2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

Thomas Charles Reilly net worth and biography

Thomas Reilly Biography and Net Worth

CFO of Cara Therapeutics

Tom has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and abroad. Most recently he served as Head of Finance of the Allergan General Medicines business. Prior to joining Allergan, he held finance leadership positions at Novartis. He earned his bachelor’s degree in finance from Manhattan College, an M.B.A in accounting from Seton Hall University and is a certified public accountant.

How do I contact Thomas Charles Reilly?: The corporate mailing address for Mr. Reilly and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Thomas Charles Reilly's contact information.
Has Thomas Charles Reilly been buying or selling shares of Cara Therapeutics?: Thomas Charles Reilly has not been actively trading shares of Cara Therapeutics during the past quarter. Most recently, Thomas Charles Reilly sold 2,044 shares of the business's stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $11.38, for a transaction totalling $23,260.72. Learn More on Thomas Charles Reilly's trading history.
Who are Cara Therapeutics' active insiders?: Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (Pres), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.
Are insiders buying or selling shares of Cara Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 60,503 shares worth more than $33,858.03. The most recent insider tranaction occured on May, 2nd when CEO Christopher Posner sold 3,936 shares worth more than $2,952.00. Insiders at Cara Therapeutics own 3.1% of the company. Learn More about insider trades at Cara Therapeutics.
Information on this page was last updated on 5/2/2024.

Thomas Charles Reilly Insider Trading History at Cara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2022	Sell	2,044	$11.38	$23,260.72
8/30/2021	Sell	1,982	$14.20	$28,144.40

Thomas Charles Reilly Buying and Selling Activity at Cara Therapeutics

Cara Therapeutics Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $0.31

$0.30

$0.32

50 Day Range

MA: $0.29

$0.25

$0.35

2 Week Range

Now: $0.31

$0.24

$1.31

Volume

204,481 shs

Average Volume

649,210 shs

Market Capitalization

$16.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68